<DOC>
	<DOCNO>NCT00038506</DOCNO>
	<brief_summary>This study 48-week study evaluate efficacy safety investigational regimen combine FDA approve HIV drug antiretroviral-experienced subject fail first highly active antiretroviral therapy regimen .</brief_summary>
	<brief_title>Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Currently initial HAART ( highly active antiretroviral therapy ) regimen 3TC/ZDV 3TC/d4T PI ( protease inhibitor ) boost unboosted NNRTI ( nonnucleoside reverse transcriptase inhibitor ) . Plasma HIV 1 RNA &lt; 400 copies/ml least 2 documented occasion prior viral rebound . Have plasma HIV 1 RNA value &gt; 400 copies/ml &lt; 10,000 copies/ml 2 document successive occasion ( include screen ) separate least 2 week . A CD4+ lymphocyte count less equal 100 . Have take Abacavir ( ZIAGEN TRIZIVIR ) tenofovir ( VIREAD ) previously . Have AIDS define illness within 30 day screen . Pregnant breastfeeding . Specified viral genotype upon screen . And inclusion exclusion criterion evaluate physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 TRIZIVIR Tenofovir</keyword>
</DOC>